This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting a study, entitled, 'PET Imaging of Brain Amyloid Using [11C]MeS-IMPY.'Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain. For this purpose, positron emission tomography (PET) and a research drug called [11C]MeS-IMPY will be used. This drug is radioactively labeled and has never been previously administered to human subjects. This drug will be injected intravenously, and PET will then take 'pictures' over time of the amount of drug in the subject's brain. The study is being conducted at GUMC and the NIH. At the Georgetown site, we will recruit a maximum of 15 subjects who have Alzheimer's disease. This study requires that subjects come to the NIH as an outpatient for approximately 3-4 visits. A subject will be registered as an NIH patient, and asked to sign the PET and magnetic resonance imaging (MRI) consent form. The following tasks will be performed during the visits: EVALUATION, MRI, PET, and the laboratory tests approximately 24 hours after PET scan. Subjects will receive their initial evaluation at Georgetown, and will obtain their MRI and PET Scans and subsequent laboratory tests at NIH. The order of the MRI and PET visits may be interchanged, depending upon the availability of the scanner.
Showing the most recent 10 out of 128 publications
